Viruses tailored to kill specific bacteria saved patients when antibiotics failed. Engineered bacteriophages cleared drug-resistant infections in compassionate-use cases. The revival offers a weapon against superbugs.
Viruses as medicine
The agents are natural. Phages infect and kill bacteria selectively. They evolved for the job.
Engineered precision
Design sharpened them. Genetic tweaks improved killing and reduced resistance. Targeting is fine.
Dramatic rescues
Cases inspired. Patients out of options recovered. Reports drew attention.
Personalized therapy
Matching matters. Phages are chosen for each infection. Bespoke cocktails result.
Regulatory gaps
Hurdles remain. Rules for personalized viruses are unsettled. Trials are hard to design.
Renewed interest
Momentum grew. Centers and companies invest. The old idea returns.
The bottom line
Engineered bacteriophages cleared drug-resistant infections in compassionate-use cases, reviving phage therapy. Treatment is personalized to each infection. Regulatory frameworks lag the renewed interest.
